% | $
Quotes you view appear here for quick access.

Endocyte, Inc. Message Board

  • bigcudllyhunk bigcudllyhunk Jun 18, 2014 9:40 AM Flag

    Endocyte defended at RBC

    RBC Capital Mkts lowers their ECYT tgt to $15 from $20. Merck (MRK) terminated vintafolide partnership; still waiting on Phase II OS data though. Phase II OS data in NSCLC are expected in 3Q:14 (potentially ESMO), which could still show a benefit for vintafolide treated patients since no one has seen the data to date. They would expect a positive, albeit muted, reaction but overall it would be an important validation for ECYT's technology and platform. EC1456 and other Phase I data will be more important now; expected in 2014 and 2015. Though less likely, others could still have partnering interest; cash per share is ~$5-6

    Read more:

    SortNewest  |  Oldest  |  Most Replied Expand all replies
3.77-0.10(-2.58%)May 26 4:00 PMEDT